

MARY ELLEN CLYNE, Ph.D.
President and Chief Executive Officer
Clara Maass Medical Center

BARRY H. OSTROWSKY
President and Chief Executive Officer
Barnabas Health

Dear Manufacturers,

I am writing on behalf of Clara Maass Medical Center (CMMC; 340B ID# DSH310009) to inform manufacturers that CMMC recently underwent an audit by the Health Resources and Services Administration (HRSA) of CMMC's compliance with 340B Drug Pricing Program (340B Program) requirements.

As background, CMMC qualified for the 340B Program as a Disproportionate Share Hospital (DSH) located at One Clara Maass Drive, Belleville, New Jersey, 07109 and has participated in the 340B Program since January 1, 2011.

Through the audit process, CMMC was found to have non-compliance within their 340B Program and responsible for repayment as a result of the following finding(s):

CMMC obtained covered outpatient drugs through a group purchasing organization (GPO)

CMMC dispensed 340B drugs to ineligible individuals, as prohibited by section 340B(a)(5)(B) of the Public Health Service Act

CMMC has identified all affected manufacturers and has contacted each to notify them of these violations to begin a dialogue on a method for repayment to affected manufacturers. If manufacturers have not received notification from CMMC and believe repayment may be owed for the violations described in this letter, or if you have any questions or comments regarding the violations described in this letter please contact me at 973-450-2002 or via email at Mclyne@barnabashealth.org and/or Robert Pellechio at 973-322-4367 or via email at Rpellechio@barnabashealth.org.

Sincerely,



Mary Ellen Clyne, Ph.D.
President and Chief Executive Officer
Clara Maass Medical Center